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The front-line antituberculosis drug isoniazid (INH) and the related drug ethionamide (ETH) are prodrugs
that upon activation inhibit the synthesis of mycolic acids, leading to bactericidal activity. Coresistance to INH
and ETH can be mediated by dominant mutations in the target gene inhA, encoding an enoyl-ACP reductase,
or by recessive mutations in ndh, encoding a type II NADH dehydrogenase (NdhII). To address the mechanism
of resistance mediated by the latter, we have isolated novel ndh mutants of Mycobacterium smegmatis and
Mycobacterium bovis BCG. The M. smegmatis ndh mutants were highly resistant to INH and ETH, while the M.
bovis BCG mutants had low-level resistance to INH and ETH. All mutants had defects in NdhII activity
resulting in an increase in intracellular NADH/NAD ratios. Increasing NADH levels were shown to protect
InhA against inhibition by the INH-NAD adduct formed upon INH activation. We conclude that ndhmutations
mediate a novel mechanism of resistance by increasing the NADH cellular concentration, which competitively
inhibits the binding of INH-NAD or ETH-NAD adduct to InhA.
Despite the declaration by the World Health Organization
10 years ago that tuberculosis (TB) was a global health emer-
gency, the problem has worsened primarily due to the growing
human immunodeficiency virus epidemic and the emergence
of drug resistance (9, 12). Although TB can be cured by a
regimen of several drugs for at least 6 months, the emergence
of drug-resistant and multidrug-resistant TB has created new
challenges to control and defeat the disease. According to the
World Health Organization, drug-resistant Mycobacterium tu-
berculosis strains are found in at least 72 countries at a rate
ranging from 3 to 41% (53). Understanding the mechanisms by
which drug resistance occurs is important in order to quickly
identify drug-resistant strains to treat the patients adequately.
Moreover, knowledge of resistance mechanisms leads to the
understanding of the mode of drug action and to the develop-
ment of strategies to overcome drug resistance.
Isoniazid (INH) is one of the most effective drugs used to
treat TB. INH was introduced as an antituberculosis drug in
1952 (4, 13) and, soon after, the first INH-resistant (INHr) M.
tuberculosis strains were isolated (35). It is estimated that world-
wide up to 28% of the M. tuberculosis strains are INHr, with a
median of 6.2% in new TB cases (53). In previously treated TB
cases, the percentage of INHr strains can reach up to 60% (53).
Numerous genes have been found to be associated with INH
resistance in clinical isolates (43). However, to date only two
genes, katG encoding a catalase peroxidase and inhA encoding
an NADH-dependent enoyl-ACP reductase, have been shown
to confer greater than fivefold increased susceptibility or resis-
tance to M. tuberculosis upon gene transfer (26, 56). Mutations
in katG are recessive, resulting in a loss or altered catalase
peroxidase function (and subsequent INH resistance) in both
INHr laboratory-isolated mutants and INHr clinical isolates
(17, 22, 27, 41, 43, 57). The recessive nature of the katG
mutations, i.e., the restoration of catalase peroxidase activity
and INH susceptibility when replaced or complemented with
the wild-type gene, is consistent with the fact that KatG acti-
vates INH (20, 56, 57) to generate a hypothetical isonicotinic
acyl radical that reacts with NAD and forms an INH-NAD
adduct (45). This adduct binds to and inhibits InhA (29, 40, 44,
45, 52), resulting in mycolic acid biosynthesis inhibition (49)
and cell death (49, 51). In contrast, overexpressed inhA alleles
or alleles causing amino acid substitutions within the structural
gene have been shown to confer INH resistance in a dominant
fashion, i.e., conferring INH resistance when the mutant alleles
replace or complement the wild-type gene (1, 26, 51). Muta-
tions in INHr clinical isolates of M. tuberculosis have been
mapped to the promoter region or the structural gene of inhA
(1, 2, 17, 22, 27, 31, 38, 41, 43). The dominant nature of these
mutations was consistent with the hypothesis that inhA en-
codes the target of INH (1, 23, 26).
The structural analog of INH, ethionamide (ETH), another
InhA inhibitor, has provided important insights into INH ac-
tion. Early studies of clinical strains resistant to INH revealed
that some of the strains were also coresistant to ETH and/or
thiosemicarbazone, even though the patients had never been
treated with those drugs (6, 7, 18, 28). A recent study of 41
ETH-resistant (ETHr) clinical isolates of M. tuberculosis dem-
onstrated that most of the strains were also coresistant to INH
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and that, in 51% of these strains, the ETHr and INHr pheno-
types were solely due to mutations in the inhA gene and/or its
promoter region (38). Mutations in inhA or overexpression of
inhA have previously been shown to confer resistance in a
dominant fashion to ETH and INH (1, 26). Like INH, ETH
appears to be a prodrug that is activated by the monooxygen-
ase EthA (3, 10, 14, 50). An ETH-NAD adduct had been
hypothesized to be the inhibitor of InhA (45).
Coresistance to INH and ETH has also been shown to be
mediated in a recessive fashion in Mycobacterium smegmatis by
mutations in ndh, a gene encoding a type II NADH dehydro-
genase (NdhII) (36). The orthologue NdhII protein has been
characterized in Escherichia coli as a membrane-bound, mo-
nomeric, non-proton-translocating flavoprotein that oxidizes
NADH, reduces quinone, and catalyzes the transfer of elec-
trons from the reduced flavin to quinones (15, 19, 21, 32, 54).
The M. tuberculosis genome contains genes encoding both
NdhII (ndh; Rv1584c) and the type I NADH dehydrogenase
(NdhI) (nuoA-N; Rv3145 to -3158). The orthologue NdhI pro-
tein has been characterized in E. coli as a membrane-associ-
ated, multimeric, energy-coupling, proton-translocating en-
zyme that oxidizes NADH and pumps protons across the
membrane using the energy generated by the redox reaction
(15, 21, 54, 55). Mutations in ndh have been identified in INHr
clinical isolates of M. tuberculosis (27), but no complementa-
tion experiments were done to show that the INH resistance
phenotype was due to the ndh mutation in those strains and the
level of ETH resistance was not measured. Therefore, to dem-
onstrate that ndh mutations can cause INH and ETH resis-
tance in slow-growing mycobacteria and to elucidate the mech-
anism of INH and ETH resistance due to ndh mutations in
mycobacteria, we sought to isolate spontaneous ndh mutants in
fast- and slow-growing mycobacteria. In this report, we de-
scribe the isolation and genetic characterization of spontane-
ous ndh mutants in M. smegmatis and Mycobacterium bovis
BCG. In addition, we analyze the NdhII activity and the re-
sulting NADH/NAD ratios in the INH and ETH coresistant
mutants and propose a new mechanism for INH and ETH
resistance in mycobacteria.
MATERIALS AND METHODS
Bacterial strains, plasmids, and media. The M. smegmatis, M. bovis BCG, and
M. tuberculosis H37Rv mutants were obtained from laboratory stocks. The plas-
mids used in this study were described previously (26, 36). The M. smegmatis
strains were grown in Middlebrook 7H9 medium (Difco) supplemented with
10% (vol/vol) ADS enrichment (50 g of albumin, 20 g of dextrose, 8.5 g of sodium
chloride in 1 liter water), 0.2% (vol/vol) glycerol, and 0.5% (vol/vol) Tween 80.
The M. bovis BCG and M. tuberculosis H37Rv strains were grown in Middlebrook
7H9 medium (Difco) supplemented with 10% (vol/vol) OADC enrichment
(Difco), 0.2% (vol/vol) glycerol, and 0.05% (vol/vol) Tween 80. The solid me-
dium used was the same as that described above with the addition of 1.5%
(wt/vol) agar.
Isolation of spontaneous mutants. Mutants were isolated from non-
mutagenized cultures grown in the media described above. The cultures were
incubated with shaking at 30°C for M. smegmatis and at 37°C for M. bovis BCG
and M. tuberculosis H37Rv until they reached an optical density at 600 nm
(OD600) of at least 1.0. Tenfold serial dilutions were then plated on agar plates
(media described above) containing either INH (25 g/ml) for M. smegmatis
mutant isolation or INH (0.25 g/ml) and ETH (5 or 10 g/ml) for M. bovis BCG
and M. tuberculosis H37Rv mutant isolation. The plates were then incubated at
30°C for 7 days for M. smegmatis mutant isolation or at 37°C for 4 to 6 weeks for
M. bovis BCG and M. tuberculosis H37Rv mutant isolation.
Assessment of Ts lethality phenotype. The M. smegmatis ndh mutants were
grown to stationary phase at 30°C. Tenfold serial dilutions were plated onto two
sets of plates: one set was incubated at 30°C for 7 days (for titration of the
cultures) and the other set was incubated at 42°C for 5 days. The plates incubated
at 42°C were then shifted to 30°C, and the incubation continued for 7 days. A
strain was considered to have a temperature-sensitive (Ts) lethal phenotype if
less than 10% of its population could survive the incubation at 42°C (measured
by the number of CFU per milliliter obtained after 5 days at 42°C followed by 7
days at 30°C divided by the titer).
MIC determination. Mycobacterial cultures were grown to an OD600 of 1.0.
Tenfold serial dilutions were plated on plates containing the following drug
concentrations: for M. smegmatis strains, INH (0, 5, 10, 25, 50, 100 g/ml), ETH
(0, 5, 10, 25, 50, 100 g/ml), triclosan (TRC; 0, 5, 10, 15, 25, 50 g/ml), strep-
tomycin (0.1, 0.25, 0.5, 1 g/ml), ethambutol (0.1, 0.25, 0.5, 1, 5 g/ml), and
rifampin (5, 10, 25, 50, 75, 100 g/ml); for M. bovis BCG strains, INH (0, 0.1, 0.2,
0.25, 0.3, 0.4, 0.5, 0.6, 0.8, 1 g/ml), ETH (0, 2.5, 5, 10, 12.5, 15, 20 g/ml), and
TRC (0, 5, 10, 12.5, 15, 20 g/ml). The MIC was determined as the concentration
of drug that reduced the number of CFU per milliliter by 99%.
PCR amplification. The ndh gene was amplified from chromosomal DNA
using the following primers: for M. smegmatis, TW96 (5-CGAGGAGCATCA
ATGAGCCA-3) and TW97 (5-CTCGACCGAACCGGCTAGGA-3); for
M. bovis BCG, TW539 (5-CTGACCGGTTGGCTGGTAA-3) and NDHB2
(5-CGGATCCAGCAGCGGAACATGAG-3). The products were directly se-
quenced bidirectionally, and the sequences were aligned against each other and
the wild-type sequence.
Transformation experiments. M. smegmatis strains (10-ml cultures) were
grown at 30°C to mid-log phase (OD600  0.7), washed twice with 10% cold
glycerol, and resuspended in cold 10% glycerol (0.5 ml). To perform transfor-
mations, the cold cell suspension (150 l) was added to the plasmid (1.5 l) and
then electroporated using the following parameters: 2.5 V, 25 F, and 1,000 .
Medium (1 ml) was added to the suspension, which was incubated at 30°C for 5 h,
and then plated. For M. bovis BCG strains, the same protocol was followed, but
cell preparation and electroporation were performed at room temperature and
incubation was done at 37°C (25).
NADH dehydrogenase assays. Cultures (500 ml) were grown to mid-log phase
(OD600  0.7), spun down, and washed twice in cold phosphate buffer (50 mM
K2HPO4 [pH 7.5], 5 mM MgSO4). The cell pellet was weighed and resuspended
in cold phosphate buffer (1 ml/g of pellet). DNase and proteinase inhibitors were
added to the cell suspension, and the cells were broken using a French press
(four passages; 1,000 lb/in2/cm2). The cell debris was removed by centrifugation
(12,000  g, 20 min), and the membrane fraction was isolated by ultracentrifu-
gation (100,000  g, 90 min). The membrane fraction was then resuspended in
phosphate buffer, and protein concentration was measured using the Bio-Rad
protein assay. NADH dehydrogenase activities (type I and II) were assayed
spectrophotometrically, in the membrane fractions, at room temperature, by
measuring the rate of NHDH (reduced nicotinamide hypoxanthine dinucleotide)
oxidation at 340 nm (type I) or the rate of NADH oxidation in the presence of
menadione (2 mM) at 340 nm (type II), or by measuring the rate of 2,6-
dichloroindophenol (DCIP) reduction at 610 nm in the presence of NHDH (type
I) or NADH (type II) (36).
Determination of NADH and NAD cellular concentrations. Mycobacterial
cultures were grown to an OD600 ranging from 0.8 to 1.2. A sample of the
cultures (1 ml) was spun, and the cell pellets were resuspended in 0.2 M HCl (0.3
ml, NAD extraction) or 0.2 M NaOH (0.3 ml, NADH extraction). After 10 min
at 55°C, the suspensions were cooled to 0°C and neutralized by adding 0.1 M
NaOH (0.3 ml, NAD extraction) or 0.1 M HCl (0.3 ml, NADH extraction)
while vortexing at high speed. After centrifugation, the supernatants were col-
lected and transferred to a new tube and used immediately. The concentration of
NAD (or NADH) was obtained by measuring spectrophotometrically the rate
of 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide reduction by the
yeast type II alcohol dehydrogenase in the presence of phenazine ethosulfate at
570 nm (30, 46). The rate of 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium
bromide reduction is proportional to the concentration of nucleotide.
Quantification of the inhA expression levels. Total RNA extractions, cDNA
synthesis, and quantitative PCR with molecular beacons were performed as
described previously (26).
Western blot analysis. M. bovis BCG mid-log-phase cultures (10 ml) were
resuspended in 0.8 ml of phosphate buffer (phosphate-buffered saline; 20 mM
K2HPO4 [pH 7.5], 0.15 M NaCl) and disrupted during 10 min using a Branson
Sonifier 450. Equal amounts of protein (25 g/lane) were then separated on a
sodium dodecyl sulfate–12% polyacrylamide gel as described previously (24).
After electrophoresis, the proteins were transferred onto a Hybond-C Extra
membrane (Amersham). Membranes were then saturated with 2% dry milk in
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phosphate-buffered saline–0.1% Tween 20 and incubated overnight with rabbit
anti-InhA antibodies raised against the M. tuberculosis InhA protein (23) (dilu-
tion, 1/30,000). Membranes were then washed and incubated with anti-rabbit
antibodies conjugated to alkaline phosphatase (1/7,000 dilution; Promega).
InhA enzymatic activity assay. All assays were carried out on a Cary 100 Bio
Spectrophotometer by monitoring oxidation of NADH at 340 nm. The M. tuber-
culosis InhA protein was expressed and purified as previously described (42).
Three different procedures were used to assay the activity of M. tuberculosis InhA
with increasing concentration of NADH. In the first experiment, the INH-NAD
adduct was presynthesized by adding Mn(III) pyrophosphate (4 mM) into a
mixture consisting of INH (2 mM) and NAD (2 mM) in 100 mM potassium
phosphate buffer solution, pH 7.5 (40). The assay was performed by incubating
InhA (60 nM) with increasing concentrations of NADH (10, 100, or 500 M or
1 mM) and the INH-NAD adduct solution (10 M) for 20 min in 100 mM
potassium phosphate buffer solution, pH 7.5 (40). The reaction was initiated by
adding 2-trans-dodecenoyl-coenzyme A (CoA) (50 M). In the second assay,
InhA (60 nM) was mixed together with NADH (10, 100, or 500 M or 1 mM),
INH (10 M), and Mn(III) pyrophosphate (20 M) in 100 mM potassium
phosphate buffer solution, pH 7.5, and the reaction was initiated by adding
2-trans-dodecenoyl-CoA (50 M). In the third experiment, the INH-NAD ad-
duct was presynthesized (as described for the first experiment) and incubated
with InhA (5 M) for 3 h, followed by separation using a Hi-Trap (5-ml)
desalting column. The InhA-inhibitor complex was collected and assayed as in
the first experiment.
RESULTS
Isolation of novel ndh mutants in M. smegmatis. We have
previously shown that spontaneous M. smegmatis ndh mutants
could be isolated by plating nonmutagenized M. smegmatis
cultures onto rich medium (Mueller-Hinton) plates containing
INH (25 g/ml; five times the MIC), incubating the plates at
30°C, and then screening for the mutants that failed to grow at
42°C (36). These mutants were found to have pleiotropic mu-
tations in ndh conferring four independent phenotypes: INH
resistance, ETH resistance, temperature sensitivity, and aux-
otrophy. In an attempt to identify novel alleles mapping to ndh
involved in INH resistance, we isolated spontaneous INHr
mutants by plating 10-fold serial dilutions of 10 independent,
nonmutagenized M. smegmatis cultures onto minimal medium
Middlebrook 7H10 plates containing 25 g of INH/ml. INHr
mutants were isolated at a frequency ranging from 8  107 to
9  108. When screening for thermosensitivity, 6 to 18% of
these mutants were temperature sensitive for growth at 42°C.
We isolated 26 mutants that were INHr Ts and prototrophs.
The mutants were highly resistant to INH (MIC 50 g/ml,
with most of the mutants being resistant to more than 100
g/ml) (Table 1) but were susceptible to other antimycobac-
terial drugs, like streptomycin, ethambutol, and rifampin (data
not shown). Two other antimycobacterial agents, ETH and
TRC, both targeting InhA (1, 34), were also tested. As shown
in Table 1, the M. smegmatis mutants were highly resistant to
ETH but had a low resistance to TRC.
To test if the mutations mapped to ndh, the INHr Ts mu-
tants were transformed with pYUB803, an extrachromosomal
plasmid (pMV261 [48]) containing the M. smegmatis ndh gene,
and the resulting transformants were screened for loss of ther-
mosensitivity and INH resistance. The pYUB803 construct
restored INH sensitivity and temperature resistance pheno-
types to all the INHr Ts mutants (data not shown). Further-
more, pYUB808, a replicative plasmid (pMV261) containing
the M. bovis BCG mdh gene encoding the NADH-dependent
malate dehydrogenase, also restored thermoresistance in
all but one mutant (mc22380) (data not shown). Although
M. smegmatis does not possess the NADH-specific malate de-
hydrogenase, Miesel et al. (36) had shown that the M. bovis
BCG mdh gene was able to restore wild-type phenotypes to
M. smegmatis ndh mutants. Interestingly, Molenaar et al. (37)
postulated that Mdh allows for the restoration of the Ndh
enzymatic activity by combining with the M. smegmatis malate:
quinone oxidoreductase (Mqo) enzyme. Taken together, these
transformation studies were consistent with the hypothesis that
TABLE 1. Characterization of M. smegmatis ndh mutants
Strain ndh allele
Mutation MIC (g/ml) % Viability at
42°CaDNA Amino acid INH ETH TRC
mc2155 ndh Wild type Wild type 5 10 10 100
mc22374 ndh-64 T50C I17T 100 100 25 55
mc22375 ndh-52 A85C T29P 100 50 10 31
mc22376 ndh-101 A137C H46P 100 100 25 99
mc22377g ndh-61 G251A G84D >100 >100 25 1
mc22378 ndh-11 T299C L100P 100 >100 10 1
mc22379 ndh-16 G343Ab A115T 100 100 25 10
mc22380 ndh-13 T364A Y122N 100 100 25 10
mc22381 ndh-32 C433Tc R145C >100 >100 25 1
mc22382 ndh-41 T509C F170S 100 100 10 45
mc22383 ndh-23 G559Cd A187P 50 50 25 12
mc22384 ndh-71 T737C V246A 100 100 10 30
mc22385 ndh-17 T815A V272E 100 100 10 46
mc22386 ndh-22 T899Ge V300G 100 100 25 30
mc22387 ndh-31 G1005T Q335H 100 100 10 35
mc22388 ndh-84 T1081Cf Y361H 100 100 10 50
a Viability at 42°C was defined as the percentage of cells that survived incubation at 42°C. Ten- fold serial dilutions of mycobacterial cultures were plated at the
nonpermissive temperature (42°C). After incubation at 42°C for 4 days, the plates were incubated at the permissive temperature (30°C) for 6 days. The number of CFU
per milliliter obtained after the temperature shift was divided by the titer of the culture to give the percent viability at 42°C.
b Also found in mutant ndh-18. This was the only mutation previously isolated (36).
c Also found in mutants ndh-63 and ndh-93.
d Also found in mutant ndh-12.
e Also found in mutants ndh-24, ndh-51, and ndh-83.
f Also found in mutants ndh-62, ndh-81, ndh-82, and ndh-85.
g The M. smegmatis ndh Ts lethal mutants are shown in bold.
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all the mutants had acquired mutations in the M. smegmatis
ndh gene.
Sequence analysis revealed that all 26 mutants contained
single point mutations in the ndh gene resulting in amino
acid substitutions (Table 1). Eleven of the mutations were
found more than once. The G559C (Ala187Pro) and T1081C
(Tyr361His) mutations were found in two independent cul-
tures, whereas the C433T (Arg145Cys) and T899G (Val300Gly)
mutations were found in three independent cultures. Thus,
of the 15 unique mutations identified, only 1, the Ala115Thr
amino acid change, had been isolated previously and it, too,
was found to be a prototroph (36). The locations of the amino
acid substitutions caused by the mutations are depicted on the
protein sequence (Fig. 1). The M. smegmatis ndh gene is 1,374
bp in length, encoding an open reading frame of 458 amino acids.
All of the mutations caused amino acid substitutions from amino
acid 17 to amino acid 361 (Fig. 1). None of the mutations was
positioned in the NAD binding site and only one (Ile17Thr) was
located in the FAD binding site, but most of the mutations were
found in conserved regions of Ndh from M. tuberculosis, Myco-
bacterium leprae, and Corynebacterium glutamicum (Fig. 1).
Coresistance to INH and ETH can be mediated by ndh
mutations in M. bovis BCG. Since M. smegmatis is 100 times
more resistant to INH than M. tuberculosis or M. bovis BCG is,
FIG. 1. Sequence alignment of actinomyces NdHII proteins and mutation descriptions. The NdhII proteins from M. bovis BCG, M. tuberculosis,
M. leprae, Corynebacterium glutamicum, and M. smegmatis were aligned using BOXSHADE 3.21 (http://www.ch.embnet.org/software/BOX_form
.html). The putative FAD and NAD binding motifs (33) and transmembrane domain (TM) (http://www.cbs.dtu.dk/services/TMHMM/) (47) are
boxed, and the conserved regions have a black background. The positions and the amino acid substitutions found in M. smegmatis ndh mutants
isolated in this study and in previous studies (in parentheses) (36) are shown below the M. smegmatis alignment. The positions and the amino acid
substitutions found in M. bovis BCG ndh mutants isolated in this study are shown above the M. bovis BCG alignment (the base pair insertions are
indicated with arrows), while the positions and the amino acid changes previously isolated in M. tuberculosis clinical isolates (27) are shown in
parentheses above the M. bovis BCG alignment.
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we addressed whether ndh mutations could confer resistance
to INH and ETH in slow-growing mycobacteria. Interestingly,
a previous study identified mutations in ndh in INHr M. tuber-
culosis clinical isolates from Singapore, although no gene
transfers were performed to prove that the resistance was
directly mediated by the ndh mutations (27). Here, M. bovis
BCG Pasteur was chosen with the intention of facilitating
safety containment during French press procedures required
for biochemical analyses. To enrich for ndh mutants and to
eliminate the eventual selection of INHr strains carrying mu-
tations within the katG gene, we isolated spontaneous mutants
of M. bovis BCG resistant to both INH and ETH. The INHr
and ETHr mutants were obtained by plating 10-fold serial
dilutions of three independent M. bovis BCG cultures onto
Middlebrook 7H10 plates containing 0.25 g of INH/ml and
10 g of ETH/ml. This double antibiotic selection led to the
isolation of mutants at a frequency of 105 to 106. From 15 of
the INHr ETHr strains sequenced for mutations in the ndh
gene, 6 were found to possess mutations. Four of the six ndh
mutants had a single point mutation in the ndh gene resulting
in amino acid substitutions (Table 2; Fig. 1). The other two had
acquired a single base pair insertion, theoretically causing a
frameshift in the Ndh open reading frame (Table 2; Fig. 1).
The base pair insertions were confirmed by sequencing ndh
from two independent PCRs using two independent genomic
DNA preparations as template. All six mutants displayed low-
level resistance phenotypes to INH (2.5- to 6-fold), ETH (4- to
8-fold), and TRC (2- to 3-fold) (Table 2; Fig. 2A). Wild-type
susceptibilities to INH, ETH, and TRC could be restored in
each mutant by complementation with the wild-type M. bovis
BCG ndh gene (data not shown). This suggests that resistance
to all three drugs was directly mediated by mutations within
the ndh gene in M. bovis BCG. Notably, all six ndh mutants had
no growth defect in liquid medium without antibiotic (Fig. 2B).
Coresistance to INH and ETH in ndh mutants is not due to
InhA overexpression. Since previous studies had demonstrated
that overexpression of inhA conferred coresistance to INH and
ETH in M. smegmatis, M. bovis BCG, and M. tuberculosis (1,
26), we hypothesized that the coresistance to INH and ETH
could be mediated by the up-regulation of inhA. To test this
hypothesis, the amounts of InhA protein in three M. bovis
BCG ndh mutants (mc22401, mc22402, and mc22403) were
FIG. 2. Growth of M. bovis BCG Pasteur ndh mutants at 37°C. (A) Growth on solid media containing different concentrations (in micrograms
per milliliter) of INH of three M. bovis BCG ndh mutants (mc22400, mc22401, and mc22402). (B) The ndh mutants and parent strain were grown
in Middlebrook 7H9 broth supplemented with 10% OADC, 0.2% glycerol, and 0.05% Tween 80. The growth of the cultures was followed
spectrophotometrically by measuring the OD600.
TABLE 2. Characterization of M. bovis BCG Pasteur ndh mutants
Strain ndh allele
Mutation MIC (g/ml)
DNA Amino acid INH ETH TRC
BCG Pasteur ndh Wild type Wild type 0.1 2.5 5
mc22402 ndh-3 insbp272(a)a Frameshift 0.3 15 15
mc22403 ndh-443 insbp439(t) Frameshift 0.6 15 10
mc22404 ndh-44 C604T R202W 0.3 10 10
mc22400 ndh-33 T716C L239P 0.25 12.5 12.5
mc22401 ndh-38 T986C V329A 0.25 10 15
mc22405 ndh-55 A1097G D366G 0.3 20 10
a insbp272(a) refers to insertion base pair a at position 272.
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compared to that of the parental M. bovis BCG strain by
Western blot analysis using rabbit anti-InhA antibodies. This
analysis showed no significant differences in InhA protein lev-
els between the wild-type strain and the three M. bovis BCG
ndh mutants (Fig. 3A). A further quantification of inhA was
performed at a transcriptional level in two independent M.
bovis BCG mutants (mc22401 and mc22402) using a molecular
beacon mRNA assay (26) in the absence or presence of INH.
Figure 3B shows that the level of inhA mRNA was similar in all
strains tested, thus confirming the results obtained by immu-
noblotting. This rules out the possibility that coresistance to
INH and ETH in the ndh M. bovis BCG mutants is mediated
by higher InhA levels. Moreover, no increase in the levels of
inhA mRNA was observed in the various strains, independent
of the concentration of INH used (0, 0.1, or 1 g/ml) (Fig. 3B).
In contrast, M. tuberculosis transformed with pMV261::inhA,
which has been previously shown to be coresistant to INH and
ETH (26), showed a five- to sixfold increase in inhA mRNA
levels. From these studies, we conclude that the coresistance to
INH and ETH in the ndh mutants did not result from in-
creased levels of inhA expression.
The ndh mutants are defective in NdhII activity. The iden-
tification of mutations in ndh suggested that the strains would
be defective in NdhII activity. Therefore, the NdhII enzymatic
activities were determined in the membrane fractions of the
unique ndh mutants and six complemented mutants by mea-
suring the rate of NADH oxidation in presence of menadione
(Table 3; Fig. 4). In M. smegmatis, the level of NdhII activity of
the different ndh mutants ranged from 5 to 48% of the activity
of the wild-type strain, mc2155. In M. bovis BCG, all six M.
bovis BCG ndh mutants lost between 75 and 90% of their
NdhII activity (Fig. 4A). For comparison, we measured the
NdhII activity in an INHr M. bovis BCG mutant having a single
point mutation in katG (G985T, resulting in an Asp329Tyr
amino acid change) and found it similar to that of the wild type
(Fig. 4A). Complementation with pMV261::ndh restored NdhII
activity in the mutants from both species to wild-type levels,
suggesting that overexpression of a wild-type ndh gene could
functionally restore the defect of NdhII activity in the mutants
(Table 3; Fig. 4B).
The NdhI activity was also assayed by measuring the rate of
DCIP reduction in the presence of NHDH, as we were not able
to measure the rate of NHDH oxidation in the presence of
menadione. The NdhI activity was on average 95% lower than
the NdhII activity (assayed by measuring the rate of DCIP
reduction in the presence of NADH) in M. smegmatis mc2155
and 75% lower in wild-type M. bovis BCG. The M. smegmatis
and M. bovis BCG ndh mutants had an NdhI activity compa-
rable to that of the wild-type strains (data not shown).
ndhmutations result in altered NADH/NAD ratios in cells.
Since NdhII encoded by ndh oxidizes NADH into NAD, we
reasoned that the mutants with lowered NADH dehydroge-
nase activity would have an altered NADH/NAD ratio in the
cells. To test this hypothesis, both intracellular NADH and
NAD concentrations were measured using a sensitive cycling
assay (30). Each mutant was grown at permissive temperature
in broth containing neither INH nor ETH in a culture flask
fully aerated. The NADH and NAD levels were found to be
highly dependent on the density of the culture in that higher
levels of NADH and NAD were measured in denser cultures
(data not shown). Nevertheless, our results repeatedly showed
that the NADH/NAD ratio was significantly higher in the ndh
mutants than in wild-type M. smegmatis or M. bovis BCG
(NADH/NAD  0.7 in parent strains and 1.0 in the ndh
mutants; P 	 0.002). The significance was determined using
the Student t test (Table 3; Fig. 5A). As expected, in the M.
bovis BCG INHr katG mutant which had no defect in NdhII,
the NADH/NAD ratio was similar to that of the wild type
(Fig. 5A). In M. bovis BCG, we observed that the NAD con-
centrations were comparable in both the wild-type and ndh
mutants (Fig. 5C). The main difference in these mutants was
FIG. 3. InhA expression in ndh mutants. (A) Western blot analysis. Detection of InhA in total protein extracts obtained from the different
M. bovis BCG strains using rabbit anti-InhA antibodies raised against the M. tuberculosis InhA protein. (B) inhA mRNA levels in M. bovis BCG
strains and the M. tuberculosis pMV261::inhA strain without addition of INH and after 4 h of incubation in the presence of 0.1 or 1.0 g of INH/ml.
inhA values were normalized using sigA levels as reference (26). Each value is the average of three culture replicates, each of which was evaluated
three times. Error bars correspond to 95% confidence intervals. As a positive control of inhA overexpression, the M. tuberculosis strain harboring
pMV261::inhA is shown (26), tested only without antibiotic and 1.0 g of INH/ml.
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the NADH concentration, which almost doubled in the ndh
mutants compared to the wild-type strain (Fig. 5C).
The NADH and NAD concentrations were also measured
in ndh mutants transformed with the complementing pMV261::
ndh plasmid (Table 3; Fig. 5B and D). The transformants had
an NADH/NAD value (0.4 to 0.5) comparable to that of the
wild-type strains transformed with their respective pMV261::
ndh (0.3). Again, the main change between strains transformed
with either pMV261 or pMV261::ndh was observed for the
NADH concentrations, the NAD concentrations remaining
comparable (Table 3; Fig. 5D). Altogether, these results sug-
gest that coresistance to INH and ETH directly correlates with
reduced NdhII activity and increased intracellular NADH/
NAD ratios.
Increasing NADH concentrations prevent inactivation of
InhA by the INH-NAD adduct. Previous studies have estab-
lished that InhA is an NADH-specific enoyl-ACP reductase
(11, 42) that is inhibited by a specific INH-NAD adduct (29,
40, 44, 45, 52). Since we have demonstrated that coresistance
to INH and ETH in ndh mutants correlates with increased
FIG. 4. NADH dehydrogenase activity in M. bovis BCG ndh mutants and transformants. Ndh activity was measured as described in Materials
and Methods and is given as a percentage relative to wild type (either M. bovis BCG Pasteur [A] or M. bovis BCG Pasteur transformed with
pMV261 [B]). For comparison, the Ndh activity of an INHr M. bovis BCG strain having a single point mutation in katG (G985T, resulting in an
Asp329Tyr amino acid change) is shown. The experiments were repeated three times, and the average is plotted with its standard deviation.
TABLE 3. Ndh activity and NADH/NAD ratios in M. smegmatis strains
Strain % Ndh activitya [NADH] (nM)a [NAD] (nM)a [NADH]/[NAD]
mc2155 100 1,028
 22 1,379
 12 0.7
mc22374 21.0 
 1.0 1,742 
 65 1,409
 19 1.2
mc22375 44.8 
 3.8 1,525 
 31 1,132
 3 1.3
mc22376 34.0 
 3.0 2,322 
 11 1,200
 2 1.9
mc22377 4.8 
 0.8 1,966 
 90 1,222
 35 1.6
mc22378 6.8 
 0.5 1,508 
 67 836
 19 1.8
mc22379 29.2 
 4.4 1,129 
 9 1,100
 6 1.0
mc22380 48.0 
 2.0 1,760 
 21 1,502
 17 1.2
mc22381 8.0 
 0.7 1,728 
 41 1,116
 39 1.5
mc22382 13.5 
 0.7 1,845 
 105 1,335
 45 1.4
mc22383 13.8 
 0.7 1,505 
 2 1,113
 2 1.4
mc22384 17.1 
 2.2 1,268 
 37 810
 5 1.6
mc22385 15.9 
 1.5 1,230 
 105 938
 38 1.3
mc22386 18.1 
 1.8 1,525 
 31 1,132
 3 1.4
mc22387 18.2 
 2.7 1,511 
 0 1,072
 33 1.4
mc22388 24.0 
 1.1 1,316 
 20 870
 30 1.5
mc2155 pMV261 100 987
 23 1,372 
 10 0.7
mc2155 pMV261::ndh 510.4 
 55.7 362
 1 1,056 
 14 0.3
mc22378 pMV261 8.6 
 0.4 3,196 
 79 1,122
 3 2.8
mc22378 pMV261::ndh 841.3 
 50 587
 29 1,098 
 3 0.5
mc22381 pMV261 7.9 
 0.6 2,151 
 30 1,271
 29 1.7
mc22381 pMV261::ndh 584.0 
 75 577
 32 1,280 
 17 0.4
mc22377 pMV261 9.7 
 1.4 2,203 
 3 950
 22 2.3
mc22377 pMV261::ndh 587 
 66 587 
 1 1,267 
 5 0.5
a Values are means 
 standard deviations.
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NADH/NAD ratios in the mutant cells, we hypothesized that
the increased NADH concentrations mediate resistance by
competitively inhibiting the binding of the INH-NAD adduct.
Nguyen et al. (40) showed that high concentrations of NADH
can prevent inhibition of InhA by the INH-NAD adduct.
These authors reported that treatment of InhA with a 100 nM
pool of INH-NAD adducts resulted in a 78% loss of InhA
activity. However, when InhA was preincubated with 100 M
NADH and then treated with the pool of INH-NAD adducts,
no InhA inhibition was observed, suggesting that high concen-
trations of NADH protect the adduct-mediated inhibition of
InhA. To confirm the hypothesis that an excess of NADH
could prevent inactivation of InhA by the INH-NAD adduct,
the inhibition of InhA by the INH-NAD adduct was tested in
the presence of increasing concentrations of NADH under
three different conditions in vitro (Fig. 6). In the first two
FIG. 5. NADH/NAD ratios, NADH concentrations, and NAD concentrations in M. bovis BCG ndh mutants and transformants. The M. bovis
BCG strains were grown at 37°C to log phase (OD600  0.8 to 1). The NADH and NAD
 concentrations were measured in triplicate as described
in Materials and Methods. For comparison, the NADH/NAD ratio of an INHr M. bovis BCG strain having a single point mutation in katG
(G985T, resulting in an Asp329Tyr amino acid change) is shown. The experiments were repeated three times, and the average is plotted with its
standard deviation.
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experiments (experiments 1 and 2 in Fig. 6), the enzyme was
preincubated with NADH prior to the addition of the inhibitor
[either as a preformed INH-NAD adduct or as a mixture of
INH and Mn(III) pyrophosphate] and the substrate. In the
third experiment, InhA was preincubated with the INH-NAD
adduct for 3 h, and activity of the inhibited enzyme was then
assayed in the presence of different concentrations of NADH.
All three experiments yielded one consistent trend: increasing
concentrations of NADH directly correlated with a decrease in
the inhibition of InhA by the INH-NAD adduct. Therefore, we
can conclude that high levels of NADH can protect InhA from
the INH-NAD adduct, resulting in INH resistance.
Specific ndhmutations mediate a Ts bactericidal phenotype.
To further characterize the different ndh alleles, we tested
whether incubation at 42°C was a bactericidal or static event in
M. smegmatis ndh mutants. The mutants were grown at per-
missive temperature, titers were determined, and 10-fold serial
dilutions were plated on plates containing no antibiotic and
incubated at 42°C for 4 to 5 days. The plates incubated at 42°C
were then shifted to the permissive temperature (30°C) and
incubated for another 7 days. The phenotype was considered
Ts bactericidal when less than 10% of cells could survive in-
cubation at 42°C. Five ndh mutants (ndh-11 [Leu100Pro],
ndh-32 [Arg145Cys], ndh-61 [Gly84Asp], ndh-63 [Arg145Cys],
and ndh-93 [Arg145Cys]) did not survive incubation at 42°C,
and the mutations were considered bactericidal. The other mu-
tants did not grow at 42°C but were able to resume growth once
the plates were shifted to permissive temperature (30°C). In-
terestingly, the lowest NdhII activity was observed for the mu-
tants having a Ts bactericidal phenotype (mc22377, mc22378,
and mc22381) (Table 3). In broth at nonpermissive tempera-
ture (42°C), growth ceased for all bactericidal mutants as well
as five static mutants (Fig. 7A). In contrast, the seven other
static mutants grew at the nonpermissive temperature, but at a
much slower rate than wild-type M. smegmatis (Fig. 7B). After
24 h of incubation in Middlebrook 7H9 broth at nonpermissive
temperature, the drop in the number of viable cells was less
than 1 log for static ndh mutants (21 of 26), while the five
bactericidal mutants had up to a 3-log drop in viable cells (data
not shown). The reduction in viable cells was medium depen-
dent, with maximal decreases in survival in minimal medium
compared to results in tryptic soy or Mueller-Hinton broth
(data not shown). Interestingly, most of the strains with muta-
tions in the carboxy end of Ndh had no growth defect in
medium containing up to 100 g of INH/ml at the permissive
temperature (Fig. 8A), whereas strains with mutations in the
amino terminus of Ndh showed a slower growth rate with
increasing concentration of INH (Fig. 8B).
DISCUSSION
The analyses of mutations conferring resistance to drugs
have been invaluable in elucidating the mechanisms of drug
action and drug resistance. The discoveries of the phenotypes
demonstrating that inactivation of the katG (20, 56, 57) and
ethA (3, 10, 50) genes conferred resistance to INH and ETH,
respectively, established that both INH and ETH are prodrugs
with independent activation pathways. Resistance was shown
to be mediated by recessive mutations causing a loss of pro-
drug-activating activities (Fig. 9). Genetic studies demonstrat-
ing target overexpression or target alteration revealed that
INH and ETH shared a common target, InhA (1, 26). In
contrast to the mutations in the INH or ETH activator genes,
target mutations are dominant to the wild-type gene. Another
mechanism of coresistance to INH and ETH was previously
demonstrated to be mediated in M. smegmatis in a recessive
fashion by mutations in ndh, a gene encoding a type II NADH
dehydrogenase (36). It was unclear if a similar mechanism
could function in slow-growing mycobacteria such as M. tuber-
culosis or M. bovis BCG, which are 100 times more sensitive to
INH than M. smegmatis. Moreover, the precise mechanism by
which mutations in ndh could mediate coresistance to both
INH and ETH was also unclear.
To address these points, in this study 6 M. bovis BCG ndh
mutants and 14 novel M. smegmatis ndh mutants coresistant to
INH and ETH were isolated. Sequence analysis revealed the
presence of specific mutations in the ndh gene. To date, no
INHr ETHr M. tuberculosis mutants could be isolated in three
independent attempts by directly plating M. tuberculosis
H37Rv on INH and ETH plates, as done for M. bovis BCG
(data not shown). We tried to obtain the ndh mutant strains
found in INHr clinical isolates of M. tuberculosis described
previously (27), but these strains were not saved. Our inability
to isolate M. tuberculosis H37Rv ndh mutants might result from
the concentrations of drugs used to do the screening for this
particular strain, and it may reflect metabolic differences
among M. tuberculosis strains. Interestingly, Middlebrook and
Cohn had described the presence of INHr mutants that were
catalase positive but failed to grow on Middlebrook minimal
medium (35). It may be that ndh mutants of M. tuberculosis are
auxotrophic for certain nutrients, as observed for some M.
smegmatis mutants (36). Further analyses are under way to
explore these possibilities. Nevertheless, complementation of
FIG. 6. InhA activity versus NADH concentration. In experiment
1, the INH-NAD adduct was first prepared by adding Mn(III) pyro-
phosphate (4 mM) into a mixture of INH (2 mM) and NAD (2 mM).
InhA (60 nM) and NADH (10, 100, or 500 M or 1 mM) were
preincubated for 20 min prior to the addition of the INH-NAD adduct
(10 M). The reaction was initiated by the addition of 2-trans-dode-
cenoyl-CoA (50 M). In experiment 2, InhA (60 nM) and NADH (10,
100, 500, or 1,000 M) were preincubated for 20 min. INH (10 M)
and Mn(III) pyrophosphate (20 M) were then added. The mixture
was incubated for another 5 min before adding 2-trans-dodecenoyl-
CoA (50 M). In experiment 3, the INH-NAD adduct was prepared as
in experiment 1 and incubated with InhA (5 M) for 3 h. The inhibited
InhA was separated from other components by using a desalting col-
umn, and the inhibited InhA (60 nM) was assayed under different
concentrations of NADH (10, 100, or 500 M or 1 mM). In each ex-
periment, the InhA activity was assayed by monitoring the NADH
absorption at 340 nm for 2 min, at room temperature, using 2-trans-
dodecenoyl-CoA (50 M) as a substrate.
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the M. bovis BCG ndh mutations with the wild-type M. bovis
BCG ndh gene restored full susceptibility to both INH and
ETH, proving that these ndh mutations were sufficient to me-
diate the INH and ETH coresistance phenotypes in the M.
tuberculosis complex.
The phenotype of coresistance mediated by mutations in
inhA and ndh suggests that both INH and ETH target a com-
mon enzyme, InhA, and share a common mechanism of action.
To address the molecular mechanism of resistance mediated
by the ndh mutations, we first looked at the possibility that ndh
mutations mediate coresistance to INH and ETH by overex-
pressing inhA. Using a quantitative PCR test, we were able to
establish that the levels of inhA were not increased in the M.
bovis BCG mutants analyzed. This was further confirmed at a
translational level by Western blotting.
It was previously postulated that an NdhII defect in M.
smegmatis would result in an altered NADH/NAD ratio due
to an increase in the NADH concentration, which would
prevent InhA inhibition (36, 45). To test this hypothesis, the
NADH/NAD ratios were measured in all the M. bovis BCG
and M. smegmatis ndh mutants and found to be greater than
1.0 in M. smegmatis and greater than 1.6 in M. bovis BCG,
compared to 0.7 for the wild-type strains. In fact, the increase
in the NADH/NAD ratios was mostly due to an increase in
FIG. 7. Effect of nonpermissive temperature (42°C) on M. smegmatis ndh Ts mutants in liquid media. The ndh mutants were grown at 30°C to
mid-log phase, diluted to an OD600 of 0.2, and shifted to 42°C (t  0). The growth of the cultures was followed spectrophotometrically by
measuring the OD600. To simplify the figures, only four mutants are shown per group. (A) Growth was ceased for the following M. smegmatis ndh
Ts mutants: mc22374, mc22375, mc22376, mc22377, mc22378, mc22381, mc22383, and mc22385. (B) Shift to 42°C slows the growth of the following
M. smegmatis ndh Ts mutants: mc22379, mc22380, mc22382, mc22384, mc22386, mc22387, and mc22388.
FIG. 8. Growth of M. smegmatis ndh mutants at permissive temperature (30°C) with and without INH. The ndh mutants were grown at 30°C
to mid-log phase and diluted to an OD600 of 0.05. The diluted cultures (10 ml) were added to four square bottles, and to each square bottle was
added 0, 25, 50, or 100 g of INH/ml. The cultures were incubated while shaking at 30°C. The growth of the cultures was followed spectropho-
tometrically by measuring the OD600. To simplify the figures, only one mutant is shown per group. (A) Typical growth curve for M. smegmatis ndh
mutants not affected by INH, such as mc22374, mc22376, mc22378, mc22379, mc22380, mc22381, and mc22384 (mutant shown is mc22384).
(B) Typical growth curves of M. smegmatis ndh mutants with a growth rate delayed by INH, such as mc22375, mc22377, mc22382, mc22383, mc22385,
mc22386, mc22387, and mc22388 (mutant shown is mc22377).
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the NADH concentration. Nguyen et al. (40) first showed that
preincubation of InhA with NADH prevented inhibition of
InhA by the INH-NAD adduct. Our in vitro biochemical assays
showed that increasing concentrations of NADH competitively
inhibit binding of the INH-NAD adduct to InhA, irrespective
of the order of addition of the different substrates or inhibitors
to the InhA enzyme. Although the concentrations of NADH in
these experiments are higher than the intracellular physiolog-
ical concentrations present in the cells, it is unclear what the
localized concentrations of NADH and INH-NAD adduct
might be for InhA. The in vitro trend of protection from
inhibition is fully consistent with the intracellular NADH in-
crease observed for all ndh mutants. Therefore, we conclude
that increased NADH/NAD ratios most likely competitively
inhibit the binding of the INH-NAD or ETH-NAD adduct to
InhA, thus resulting in INH and ETH resistance.
An alternative hypothesis was that the altered NADH/
NAD ratios reduced or inhibited the activities of KatG and
FIG. 9. Proposed mechanism of action of INH and ETH. INH and ETH are both prodrugs that are activated by the catalase-peroxidase KatG
or the monooxygenase EthA, respectively. The activated forms react with NAD to form an INH-NAD or ETH-NAD adduct. These adducts
inhibit the common target InhA, the NADH-dependent enoyl-ACP reductase of the fatty acid synthase type II system, resulting in mycolic acid
biosynthesis inhibition and cell lysis. Resistance to INH or ETH is associated with recessive mutations in the genes encoding the activators of the
drugs, katG and ethA, respectively, which prevent drug activation. Coresistance to INH and ETH is associated with dominant mutations in the gene
encoding the common target of the drugs, inhA, which result in target amplification or target modification. A novel mechanism of coresistance to
INH and ETH is by recessive mutations in ndh, which increase the NADH intracellular concentration and cause resistance by competitively
inhibiting the binding of the INH-NAD or ETH-NAD adduct to InhA. This working model accounts for all known resistance phenotypes that have
been transferred from drug-sensitive to drug-resistant strains to date.
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EthA, the activators of INH and ETH, respectively. However,
Miesel et al. (36) showed that M. smegmatis ndh mutations
causing INH resistance did not result in decreased KatG ex-
pression. Moreover, Fraaije et al. (14) reported that EthA,
a FAD-containing monooxygenase, uses NADPH and not
NADH as a cofactor. Thus, it appears that a high concentra-
tion of NADH does not prevent activation of INH or ETH.
We conclude that both INH and ETH are prodrugs which,
when activated, form adducts with NAD, and the resulting
INH-NAD and ETH-NAD adducts inactivate InhA (Fig. 9).
We further conclude that InhA is the single primary target of
action for both INH and ETH. Low-level resistance to these
drugs is mediated by altering the NADH/NAD ratios. This
alteration might be mediated by other metabolic enzymes than
NdhII. Supporting this premise, the M. bovis BCG mutants
isolated in our screen, which are coresistant to INH and ETH
but have no mutations in ndh (see Results), have altered
NADH/NAD ratios (C. Vilche`ze and W. R. Jacobs, Jr., un-
published results). Efforts are under way to genetically identify
the mutated genes in these strains. In addition, a number of
clinical isolates of M. tuberculosis have been identified which
are resistant to INH or coresistant to INH and ETH and
possess no mutations in either inhA or ndh (38, 43). We pos-
tulate that such mutations could (i) mediate overexpression of
inhA, (ii) alter ndh expression levels, or (iii) metabolically alter
the NADH/NAD ratios. The mdh gene represents such a
candidate (36), as well as the glf and ceoBC genes, which may
contribute to INH resistance (8). Interestingly, the products of
the glf and ceoBC genes are NAD binding proteins. Further-
more, mutations altering the NADH/NAD ratio might pro-
vide useful tools to elucidate key regulators of energy metab-
olism in this postgenomic era of biology.
The role that NdhII plays in cell metabolism has been un-
clear, but it has been proposed that NdhII might control the
NADH pool to regulate cell energy metabolism (5, 16, 39).
INHr ETHr M. smegmatis and M. bovis BCG ndh mutants have
defective NdhII activity, resulting in altered NADH/NAD
ratios. Complementation of the mutants with a wild-type ndh
gene restored drug sensitivity, NdhII activity, and a NADH/
NAD ratio similar to wild type. Therefore, it appears that
NdhII is a major regulator of the NADH/NAD ratio in cells
during exponential, aerobic growth for both fast- and slow-
growing mycobacteria. The mutations that cause the reduced
NdhII activity are distributed throughout the first 80% of the
protein. Interestingly, according to the TransMembrane Hid-
den Markov model algorithm website (http://www.cbs.dtu.dk
/services/TMHMM/), which predicts transmembrane domains,
the NdhII protein of Mycobacterium species and related
Corynebacterium contains a single transmembrane-spanning
region, a region where no mutations have yet to be observed
(Fig. 1). In contrast to the E. coli enzyme, which has been
characterized as a membrane-bound protein, the mycobacte-
rial NdhII enzyme appears to be membrane associated. Inter-
estingly, all the mutations in ndh in M. smegmatis confer a Ts
phenotype to the growth of M. smegmatis. The numbers of
independent mutants isolated to date (Fig. 1) would argue that
the Ts phenotype results not from Ts NdhII activity but rather
from a conditional growth arrest caused by the altered NADH/
NAD ratio, stabilizing activity. Certain mutants in ndh have
been shown to lead to auxotrophies (36), suggesting that al-
tered NADH/NAD ratios do affect overall metabolism, a rea-
sonable expectation for the important electron donor NADH.
The mutations that alter NdhII activity from M. smegmatis
could be readily classified based on their Ts phenotypes, which
allowed us to test if thermal inactivation was either a bacteri-
ostatic or bactericidal event. A set of mutations (Gly84Asp,
Leu100Pro, and Arg145Cys), found in the region between the
FAD and NAD binding sites, conferred a bactericidal effect
upon inactivation. We believe that the development of com-
pounds that target this NdhII region could lead to novel bac-
tericidal drugs against mycobacterial pathogens. Further work
to characterize these bactericidal biochemical events following
thermal inactivation may provide insight into a novel mecha-
nism by which mycobacterial cells die, thereby providing a
rationale for designing better antimycobacterial drugs.
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